// App-Quantinova.ai

1811 : Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Researchers

Presenter

  • Hesam Hekmatjou

Principal Investigators

  • Gail J. Roboz

  • Ellen K. Ritchie

  • Sangmin Lee

  • Pinkal Desai

  • Joseph M. Scandura

  • Sandra Allen-Bard

  • Paul Christos

  • Richard T. Silver

  • Eric J. Feldman

Medical Centers

  • Weill Cornell New York Presbyterian, New York, NY

  • Department of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, NY

  • Weill Cornell Medicine, New York, NY

  • Division of Hematology and Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY

  • New York-Presbyterian Hospital/Weill Cornell Medicine, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Chronic Myelogenous Leukemia

  • Coronary Artery Disease

  • Dyslipidemia

  • Hypertension

  • Venous thrombosis

  • Diabetes

  • Stroke

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Interferon alpha

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved